Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 42.4% in December

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,459,615 shares, an increase of 42.4% from the November 30th total of 1,025,313 shares. Currently, 3.9% of the company’s stock are short sold. Based on an average daily volume of 476,178 shares, the short-interest ratio is presently 3.1 days. Based on an average daily volume of 476,178 shares, the short-interest ratio is presently 3.1 days. Currently, 3.9% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HOWL. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Friday, December 19th. Citigroup cut shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Finally, Bank of America decreased their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and an average price target of $3.75.

Insider Buying and Selling at Werewolf Therapeutics

In related news, Director Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $1.07, for a total value of $25,294.80. Following the sale, the director owned 2,866,488 shares of the company’s stock, valued at approximately $3,067,142.16. The trade was a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bioventures 2014 L.P. Mpm sold 83,230 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $0.97, for a total value of $80,733.10. Following the sale, the insider owned 4,784,111 shares in the company, valued at $4,640,587.67. The trade was a 1.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 5,337,021 shares of company stock worth $6,108,970. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares during the period. Nuveen LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter worth about $71,000. MPM Asset Management LLC raised its stake in Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares in the last quarter. MPM Bioimpact LLC boosted its holdings in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Finally, AQR Capital Management LLC bought a new stake in Werewolf Therapeutics in the 1st quarter valued at about $79,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

HOWL traded down $0.03 on Monday, reaching $0.62. The company had a trading volume of 1,843,894 shares, compared to its average volume of 537,565. The stock has a market cap of $30.15 million, a P/E ratio of -0.38 and a beta of 0.74. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics has a fifty-two week low of $0.56 and a fifty-two week high of $2.38. The company’s fifty day moving average is $1.08 and its 200 day moving average is $1.29.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.